Navigation Links
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
Date:2/4/2013

SANDY, Utah, Feb. 4, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products.  The general license was one of the final steps required to open the new plant in Terbuniy.  The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.

The new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin.  Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage manufactured is 1000 mg and is designed to be of use against various forms of tuberculosis. Sodium Para-Aminosalicilate can also be used in conjunction with other anti-tuberculosis medications.  The Ibuprofen manufactured is Rectal Suppositories for children and the currently manufactured dosage is 60 mg.  Betagistin Tablets are manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is used to treat Manier Syndrome which is characterized by drowsiness, nausea, reduction in hearing abilities and noise in the ears. It is also used as treatment of vestibular vertigo.

Julia Andrushkova, a company spokesperson, was quoted as saying:  "Receiving the general license for pharmaceutical products has been a major step to success for the many people involved, and for the Company in general."

Safe Harbor Statement 
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,"  "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
2. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
4. Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
5. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
8. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
9. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
10. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
11. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
(Date:5/4/2016)... 2016 According to a new ... Interface Market - Global Industry Analysis, Size, Share, Growth, ... interface (BCI) market  is expected to reach a value ... to expand at a CAGR of 14.9 % during ... A BCI device provides collaboration between the brain and ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks off the start of ... National Women’s Health Week takes place May 8-May 14. , Throughout the ... to empower women to make their health a top priority. Women everywhere are being ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations of Faith ... dying patients who have allowed those holding vigil to glimpse into the supernatural as ... hopes to help readers spiritually and practically gain insight into providing care to terminal ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TransWipe Volume ... Cut Pro X. Drag and drop a TransWipe preset between two video clips to ... smooth corner wipes to colored panels with customizable color and orientation options. TransWipe Volume ...
(Date:5/5/2016)... ... 05, 2016 , ... Pivot Point Consulting achieved ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, ... consulting services for electronic health record (EHR) solutions from Epic Systems Corporation ...
(Date:5/5/2016)... Lubbock, Texas (PRWEB) , ... May 05, 2016 , ... ... of the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is ... ensure that it meets its goals and delivers value to the wool industry., The ...
Breaking Medicine News(10 mins):